newsfilter
← Latest News
GlobeNewswire·

Ascentage Pharma to Participate in Three Upcoming Investor Conferences

  • Ascentage Pharma Group International (NASDAQ: AAPG, HKEX: 6855) announced its management will participate in three upcoming investor conferences to discuss its integrated biopharmaceutical therapies for cancer.
  • The company will attend the B. Riley Commercial/Late-Stage Oncology Best Ideas Summit with one-on-one meetings scheduled for May 18, 2026.
  • Ascentage Pharma will participate in the Stifel 2026 Virtual Targeted Oncology Forum on May 19, 2026, featuring one-on-one meetings and a fireside chat at 10:30 am EDT.
  • The company is scheduled to attend the Jefferies Global Healthcare Conference in New York on June 3, 2026, with one-on-one meetings and a presentation at 8:10 am EDT.
  • Webcasts for the Stifel fireside chat \& Jefferies presentation will be available via the Investor Relations Events page on the Ascentage Pharma website.
  • The company's pipeline includes inhibitors targeting apoptotic pathway proteins like Bcl-2 \& MDM2-p53, next-generation kinase inhibitors, \& protein degraders.
  • Olverembatinib, the first approved product, is a third-generation BCR-ABL1 inhibitor approved in China for CML patients with T315I mutations or resistance to prior TKIs, \& is covered by the China NRDL.
  • Global registrational Phase III trials for Olverembatinib are underway: POLARIS-2 for CML, POLARIS-1 for Ph+ ALL, \& POLARIS-3 for SDH-deficient GIST.
  • Lisaftoclax is a Bcl-2 inhibitor approved in China for adult CLL/SLL patients previously treated with BTK inhibitors.
  • Four global Phase III trials for Lisaftoclax are ongoing: GLORA, GLORA-2, GLORA-3, \& GLORA-4, targeting various CLL/SLL, AML, \& MDS patient populations.
  • Ascentage Pharma holds global IP rights \& maintains partnerships with major companies including Takeda, AstraZeneca, Merck, Pfizer, \& Innovent, alongside collaborations with leading research institutions.
  • The press release includes standard cautionary language regarding forward-looking statements \& risks associated with future operations.